摘要
目的:观察HJJB方[由红景天苷(H)、绞股蓝总苷(J)、姜黄素(J)、白术多糖(B)特定配比组成]对油酸钠诱导的HepG2细胞脂质沉积的干预作用,并探讨HJJB方抑制细胞脂质沉积的作用机制。方法:运用油酸钠诱导的HepG2细胞脂肪变性模型,在确定药物无毒性剂量范围的前提下,设正常组、模型组、HJJB方组和罗格列酮组,观察细胞上清液中胰岛素、葡萄糖和肿瘤坏死因子α(TNF-α)含量;细胞内甘油三酯(TG)含量及油红O染色;细胞内脂肪酸合成酶(FAS)、乙酰辅酶A羧化酶(ACCase)、丙二酰辅酶A(Malonyl-Co A)蛋白含量。结果:模型组细胞内TG、FAS、ACCase、Malonyl-CoA含量和细胞上清液中胰岛素、葡萄糖、TNF-α水平较正常组显著升高(P<0.01),HJJB方组和罗格列酮组的上述指标均显著降低(P<0.01),HJJB方组的细胞内TG、FAS、ACCase、Malonyl-Co A含量和细胞上清液中胰岛素、TNF-α水平显著低于罗格列酮组(P<0.01)。结论:HJJB方对油酸钠诱导的Hep G2细胞脂质沉积具有明显的抑制作用,其机制与抑制脂质合成和增强胰岛素敏感性有关。
Objective:To observe the intervention effect of HJJB Formula[it was formed by salidroside(H),gypenoside(J),curcumin(J),atractylodes macrocephala ploysacharide(B)according to specific proportion]on sodium oleate induced lipid deposition in HepG2 cells,and to discuss the mechanism of HJJB Formula inhibiting cell fat deposition.Methods:Using HepG2 cell steatosis model induced by sodium oleate,normal group,model group,HJJB Formula group and rosiglitazone group were set up on the premise of determining the range of non-toxic doses of drugs.The observing items including:contents of insulin,glucose and tumor necrosis factor-alpha(TNF-α)in cell supernatants;intracellular triglyceride(TG)content and oil red O staining;intracellular fatty acid synthase(FAS),acetyl coenzyme A carboxylase(ACCase)and malonyl coenzyme A(Malonyl-CoA)protein content.Results:The intracellular TG,FAS,ACCase,Malonyl-CoA content and the cell supernatant insulin,glucose and TNF-a levels of model group were significantly higher than that of normal group(P<0.01).The above indexes of HJJB Formula group and rosiglitazone group were significantly lower(P<0.01).The intracellular TG,FAS,ACCase,Malonyl-CoA contents and the cell supernatant insulin,TNF-αlevels of HJJB Formula group were significantly lower than that of rosiglitazone group(P<0.01).Conclusion:HJJB Formula can inhibit the lipid deposition of HepG2 cells induced by sodium oleate,and its mechanism is related to inhibiting lipid synthesis and enhancing insulin sensitivity.
作者
李红山
奚瑛斐
何哲耘
LI Hong-shan;XI Ying-fei;HE Zhe-yun(Department of Liver Disease,Ningbo No.2 Hospital,Ningbo 315010,China;Medical School of Ningbo University,Ningbo 315010,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2019年第12期5642-5645,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金面上项目(No.81873109),国家自然科学基金青年科学基金项目(No.81503404)
浙江省中医药科技计划项目(No.2017ZA123).